Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisJournal of Affective Disorders · 2026-03-22Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].Unknown journal · 2025-10-09Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive DisorderThe Journal of Clinical Psychiatry · 2025-03-02The role of the psychedelic experience in psilocybin treatment for treatment-resistant depressionJournal of Affective Disorders · 2024-12-17Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorderPsychedelics. · 2024-09-23347. Changes in Resting State Functional Connectivity After Psilocybin for Body Dysmorphic DisorderBiological Psychiatry · 2023-04-09Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorderJournal of Psychiatric Research · 2023-03-27Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of lifeJournal of Affective Disorders · 2023-02-02Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.New England Journal of Medicine · 2022-10-31Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language ProcessingPsyArXiv · 2022-09-29Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.Unknown journal · 2022-01-12The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trialNeuroscience Applied · 2021-12-31The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trialNeuroscience Applied · 2021-12-31